AGENDA Uniform Formulary Beneficiary Advisory Panel 16 December 2005

0700-0800	Sign-in	Naval Heritage Center Theater, 701 Pennsylvania Ave N.W, Washington, D.C. 20004
0800-0830	Welcome and Opening Remarks	MAJ Travis Watson
	Meeting Objectives	 Discuss recommendations of the DoD P&T Committee meeting 15-17 November 2005, San Antonio, TX. Discuss drugs in the therapeutic classes of: Acetylcholinesterase Inhibitor and N-Methyl D-Aspartate (NMDA) Receptor Antagonist, Nasal Corticosteroids for Allergic Rhinitis, Antidepressants (AD1), and Oral Macrolide/Ketolide Discuss prior authorization requirements for mescasermin (Increlex) injection. Review Committee recommendations, make comments, and forward to the Director, TMA, for final decision to approve, disapprove, or modify the recommendations. Entertain Private Citizen comments from 0830-0930. Minutes of this meeting are being recorded and will be reduced to writing. All comments made here today are for the record and will be published.
0830-0930	Private Citizen Comments	 Up to twelve people who may have signed up to address the panel; will be given a maximum of 5 minutes each using the microphone. Time limit will be strictly enforced. This time is set aside for public comment only and product endorsements, presentations of marketing strategies, or comments from industry are not appropriate. Any comments or questions during other times will not be acknowledged.
0930-1000	Break	
1000-1100	Present Acetylcholinesterase Inhibitor and N-Methyl D-Aspartate (NMDA) Receptor Antagonist Drug Class Review	Dr. Eugene Moore / Lt Col Brian Crownover
	Panel Q & A	
	BAP Discussion	Ms. Sydney Hickey
	Vote / Comments	<u> </u>
1100-1200	Present Nasal Corticosteroids for Allerg Rhinitis Drug Class Review	c Dr. Eugene Moore / Maj Wade Tiller / Lt Col Brian Crownover
	Panel Q & A	
	BAP Discussion	-
	Vote / Comments	Ms. Sydney Hickey
	Break	-

^{*}If any agenda item uses less than its allotted time, the remaining topics may be moved ahead of their scheduled time.

1300-1430	Present Antidepressant (AD1) Drug Class Review	Dr. Shana Trice / Maj Wade Tiller / Lt Col Brian Crownover
	Panel Q & A	Ms. Sydney Hickey
	BAP Discussion	
	Vote / Comments	
1430-1500	Break	
1500-1600	Present Oral Macrolide/Ketolide Drug Class Review	Lt Col Dave Bennett / Lt Col Brian Crownover
	Panel Q & A	
	BAP Discussion	Ms. Sydney Hickey
	Vote / Comments	
1600-1620	Present Prior Authorization requirement for mescasermin (Increlex) injection	Dr. Shana Trice
	Panel Q & A	
	BAP Discussion	Ms. Sydney Hickey
	Vote / Comments	
1620	Wrap-up/Adjourn	MAJ Travis Watson

^{*}If any agenda item uses less than its allotted time, the remaining topics may be moved ahead of their scheduled time.

0800-0830

1. Convene

The Department of Defense (DoD) Beneficiary Advisory Panel (BAP) will convene at 0800 hours on September 28, 2005 at the Naval Heritage Center Theater, 701 Pennsylvania Ave. N.W., Washington, D.C. 20004.

2. Opening Remarks and welcome to panel members and audience

- Exits from the meeting room
- Restroom facilities
- Be courteous to your neighbor
- Lunch options on your own

3. Explanation of rules under which the BAP meeting will be conducted

- Only the Panel will actively participate in today's meeting
- Only the Panel will address questions to any briefer
- All audience comments and interaction will be confined to the 0830 0930 allotted time and then only to those designated and approved to address the panel as private citizens
- Private citizen comments submitted in writing

4. Beneficiary Advisory Panel members

John Class

John Crum

Deborah Fryar

Marshall Hanson

Sydney Hickey

Rance Hutchings

Lisa Le Gette

Jeffrey Lenow

Martha Miller

Charles Partridge

Jan Prasad

Marissa Schlaifer

Robert Washington

5. Meeting objectives

0830 - 0930

6. Private Citizen comments

<u>0930 - 1000</u>

7. Break

1000 - 1100

- 8. Presentation of Acetylcholinesterase Inhibitor and N-Methyl D-Aspartate (NMDA) Receptor Antagonist drug class review (Dr. Eugene Moore / Lt Col Brian Crownover)
 - Relative Clinical Effectiveness
 - Relative Cost Effectiveness
 - UF Implementation Plan
- 9. Panel Q & A / Discussion of Acetylcholinesterase Inhibitor and N-Methyl D-Aspartate (NMDA) Receptor Antagonist (Ms. Sydney Hickey)
- 10. Vote / Comments

1100 - 1200

- 11. Presentation of Nasal Corticosteroids for Allergic Rhinitis drug class review (Dr. Eugene Moore / Maj Wade Tiller / Lt Col Brian Crownover)
 - Relative Clinical Effectiveness
 - Relative Cost Effectiveness
 - UF Implementation Plan
- 12. Panel Q & A / Discussion of Nasal Corticosteroids for Allergic Rhinitis (Ms. Sydney Hickey)
- 13. Vote / Comments

1200 - 1300

14. Lunch

1300 - 1430

- 15. Presentation of Antidepressant (AD1) drug class review (Dr. Shana Trice / Maj Wade Tiller / Lt Col Brian Crownover)
 - Relative Clinical Effectiveness
 - Relative Cost Effectiveness
 - UF Implementation Plan
- 16. Panel Q & A / Discussion of Antidepressants (AD1) (Ms. Sydney Hickey)
- 17. Vote / Comments

1430 – 1500

18. Break

<u>1500 – 1600</u>

- 19. Presentation of Oral Macrolide/Ketolide drug class review (Lt Col Dave Bennett / Lt Col Brian Crownover)
 - Relative Clinical Effectiveness
 - Relative Cost Effectiveness
 - UF Implementation Plan
- 20. Panel Q & A / Discussion of Oral Macrolide/Ketolide (Ms. Sydney Hickey)
- 21. Vote / Comments

<u>1600 - 1620</u>

- 22. Presentation of PA requirements for mescasermin (Increlex) injection (Dr. Shana Trice)
- 23. Panel Q & A / Discussion of PA requirements for mescasermin (Increlex) injection (Ms. Sydney Hickey)
- 24. Vote / Comments

1620

25. Wrap-up/Adjournment